Elucidating colorectal cancer-associated bacteria through profiling of minimally perturbed tissue-associated microbiota

Front Cell Infect Microbiol. 2023 Aug 1:13:1216024. doi: 10.3389/fcimb.2023.1216024. eCollection 2023.

Abstract

Sequencing-based interrogation of gut microbiota is a valuable approach for detecting microbes associated with colorectal cancer (CRC); however, such studies are often confounded by the effect of bowel preparation. In this study, we evaluated the viability of identifying CRC-associated mucosal bacteria through centimeter-scale profiling of the microbiota in tumors and adjacent noncancerous tissue from eleven patients who underwent colonic resection without preoperative bowel preparation. High-throughput 16S rRNA gene sequencing revealed that differences between on- and off-tumor microbiota varied considerably among patients. For some patients, phylotypes affiliated with genera previously implicated in colorectal carcinogenesis, as well as genera with less well-understood roles in CRC, were enriched in tumor tissue, whereas for other patients, on- and off-tumor microbiota were very similar. Notably, the enrichment of phylotypes in tumor-associated mucosa was highly localized and no longer apparent even a few centimeters away from the tumor. Through short-term liquid culturing and metagenomics, we further generated more than one-hundred metagenome-assembled genomes, several representing bacteria that were enriched in on-tumor samples. This is one of the first studies to analyze largely unperturbed mucosal microbiota in tissue samples from the resected colons of unprepped CRC patients. Future studies with larger cohorts are expected to clarify the causes and consequences of the observed variability in the emergence of tumor-localized microbiota among patients.

Keywords: 16S rRNA gene amplicon sequencing; bowel preparation; colorectal cancer; metagenome-assembled genomes; mucosal microbiota; unprepped colon resection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacteria / genetics
  • Colorectal Neoplasms*
  • Gastrointestinal Microbiome*
  • Humans
  • Microbiota*
  • RNA, Ribosomal, 16S / genetics

Substances

  • RNA, Ribosomal, 16S

Grants and funding

This study was supported in part by the program “The next-generation drug discovery and development technology on regulating intestinal microbiome” (NeDDTrim) of the Japan Agency for Medical Research and Development (AMED), under grants JP22ae0121035h0002 and JP21ae0121037s0301. This study further received funding from Chugai Pharmaceutical Co., Ltd. (grant AC-1-20200415123903-602601), Otsuka Pharmaceutical Co., Ltd. (grant AS2020A000543848), and Taiho Pharmaceutical Co., Ltd. (grant AS2020A000532969). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. All authors declare no other competing interests.